Wed.Jan 31, 2024

article thumbnail

Some dementia patients might have reversible symptoms caused by cirrhosis, study says

STAT

The descent into dementia can feel like traversing a minefield, coming across new symptoms without the hope of a cure. But some dementia patients, even up to 10% of people diagnosed with the condition, might actually have undiagnosed liver disease and accompanying neurological problems, a new study in JAMA Open Network suggests. Most importantly, it’s possible their liver-related brain symptoms could be resolved with treatment.

363
363
article thumbnail

Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?

PharmaVoice

The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.

264
264
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

We’re naming cancers all wrong, oncology leader says

STAT

Naming cancers solely by the organs they originate in is getting a bit old, according to Fabrice André, a medical oncologist at Gustave Roussy in France and the president-elect of the European Society of Medical Oncology. Instead, André hopes to push for a new naming system that emphasizes the molecular characteristics of a cancer, regardless of its tissue of origin.

357
357
article thumbnail

JP Morgan 2024 – Gene Kinney

pharmaphorum

In this exclusive interview, Gene Kinney, CEO of Prothena, discusses the latest developments in the field of neurodegenerative diseases such as Alzheimer's and Parkinson's. Gain insights and advancements being made in the treatment of these conditions.

122
122
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: Judge skeptical of arguments against Medicare drug price negotiation

STAT

WILMINGTON, Del. — Wednesday was the first time that a federal judge asked questions in-person of drug industry lawyers who are trying to stop Medicare from negotiating drug prices. It didn’t go well for them. AstraZeneca’s lawyers argued that Medicare’s new powers amount to a taking of their property rights without due process.

article thumbnail

Public awareness poll highlights value of Pharmacy First promotion

The Pharmacist

The importance of publicising Pharmacy First has been underlined by a new survey showing that just under half (44%) of patients were unaware of the service which launches today. The poll, held by pharmacy platform Charac in partnership with YouGov, also found that only 23% of patients are currently using pharmacies as their initial port […] The post Public awareness poll highlights value of Pharmacy First promotion appeared first on The Pharmacist.

106
106

More Trending

article thumbnail

Novartis calls time on Tim3 drug sabatolimab in MDS

pharmaphorum

Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.

137
137
article thumbnail

STAT+: Years after a polarizing approval, Biogen walks away from Aduhelm

STAT

Biogen is giving up its ownership of Aduhelm , the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history. Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s

363
363
article thumbnail

New CMS pilot to test payment scheme for pricey sickle cell gene therapies

BioPharma Dive

The agency is planning a pilot program across states to help sickle cell patients access treatments like the newly approved Casgevy and Lyfgenia.

118
118
article thumbnail

Opinion: The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments

STAT

The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade Organization to gut intellectual property protections for Covid-19 vaccines. Now, with the WTO planning to take up the issue again in late February, the administration must decide whether to support a similar proposal that would strip protections from Covid-19 treatments and diagnostics as well.

Vaccines 345
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Biogen quits Aduhelm, handing back rights to original developer

BioPharma Dive

The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.

121
121
article thumbnail

Opinion: What the pope is missing about commercial surrogacy

STAT

Over the past few years, I have watched a wonderful young boy I’ll call Chad grow up smart and full of life. His parents, a gay couple with whom I am friends, used a gestational surrogate, Mary (also a pseudonym), a kind, down-to-earth woman whom I have also met. I have been thinking of him recently when I read Pope Francis’  recent comments about surrogacy.

319
319
article thumbnail

Novo Nordisk sales surge drives value towards $500bn

pharmaphorum

A surge in 2023 sales and profits fuelled by diabetes and obesity drugs has driven Novo Nordisk's valuation toward $500bn

Diabetes 122
article thumbnail

STAT+: As supply crunch starts to ease, Novo Nordisk to offer more doses of obesity drug Wegovy to U.S. patients

STAT

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit such doses last May. The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by massive

Diabetes 325
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Using Tolerance Intervals for Evaluation of Uniformity of Dosage Units Data in Routine Batch Release

PharmaTech

This article introduces that the basic technique for tolerance interval is implemented using the conventional range 85–115% LC where the proposed range in the PF is not taken into account.

Dosage 98
article thumbnail

STAT+: Experts critique flawed system for monitoring drugs’ side effects in wake of asthma drug report

STAT

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clini

article thumbnail

WuXi Biologics achieves large-scale manufacturing milestone

European Pharmaceutical Review

A combination of four 4,000-litre single-use bioreactors reaching a 16,000-litre scale has resulted in the successful completion of WuXi Biologics’ first manufacturing run at its drug substance facility MFG7 in Ireland. This is the largest manufacturing scale for the contract research, development and manufacturing organisation’s (CRDMO) to date.

98
article thumbnail

STAT+: Obscure vertigo drug could bring rare hope for patients with devastating neuron disease

STAT

About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients.  A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

GSK sales of RSV vaccine stay strong, beating forecast

BioPharma Dive

The British drugmaker reported Arexvy sales of about $1.5 billion for 2023, higher than the range it had previously predicted for the year.

Vaccines 114
article thumbnail

Pfizer’s reset year starts with a little profit

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the final act in a pharmaceutical saga, the debate of Vertex Pharmaceuticals’ success, and news on 23andMe’s ongoing transformation.

article thumbnail

The secret to successful patient influencer marketing? Authenticity

pharmaphorum

Reverba offers innovative patient engagement solutions and strategies that utilise the power of authentic patient influencers. Discover the secret to successful patient influencer marketing and how it can benefit your healthcare organisation.

118
118
article thumbnail

STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more

STAT

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get started. Our flavor today is glazed doughnut — sweets for the sweet, you know? Meanwhile, do keep us in mind if you hear anything interesting.

Diabetes 266
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

AbbVie’s Tepkinly backed by NICE for DLBCL patients

pharmaphorum

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing form of non-Hodgkin lymphoma. Tepkinly (epcoritamab) – the first medicine to emerge from AbbVie’s $3.9 billion alliance with Genmab signed in 2020 – can be used to treat adults with DLBCL whose cancer has returned or has not responded to at least two previous systemic treatments.

112
112
article thumbnail

MHRA authorises GSK’s Omjjara for treating symptoms in adult myelofibrosis with anaemia

Outsourcing Pharma

GSK plcâs small molecule Omjjara (momelotinib), was granted marketing authorization (MA) yesterday (January 31) by the Medicines and Healthcare products Regulatory Agency (MHRA).

89
article thumbnail

Digital health hit hard by VC slump in 2023, says report

pharmaphorum

Digital health investments has halved for the second year in a row, according to a new report from CB Insights

119
119
article thumbnail

NHS launches Pharmacy First to treat seven common conditions

Pharma Times

Over 10,000 pharmacies in England will be offering the new advanced service

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

'Easy access' to antibiotics 'may or may not be a good thing'

The Pharmacist

Pharmacy First is unlikely to be a significant source of complications due to increased antibiotic use but evaluation of its impact will be key, according to a National Institute of Health Research (NIHR) senior investigator. Paul Little – who is also professor of primary care research at the University of Southampton – told an NIHR […] The post 'Easy access' to antibiotics 'may or may not be a good thing' appeared first on The Pharmacist.

89
article thumbnail

Nanotechnology-based CRISPR/Cas9 delivery system for genome editing in cancer treatment

World Pharma News

This review is designed by Professor Changyang Gong and written by his PhD student Shiyao Zhou. At the beginning, they elaborated the mechanism of CRISPR/Cas9 system. CRISPR/Cas9 system consists of Cas9 protein and single stranded directing RNA (sgRNA). In the presence of protospacer adjacent motif (PAM), sgRNA accurately leads the Cas9 endonuclease to the target regions, where it causes DNA double strand breaks (DSBs), resulting in site‐specific genomic change.

94
article thumbnail

CMS sets up negotiating framework for expensive sickle cell disease gene therapies

Pharmaceutical Technology

CMS’ CGT Access Model will see allow the agency to negotiate negotiate pricing and build a framework that expands access to treatments.

98
article thumbnail

AstraZeneca and Sanofi Beyfortus to dominate RSV market in China: GlobalData

Express Pharma

AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody (mAb), has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season. With the first approved preventive option for RSV, AstraZeneca and Sanofi will dominate the market in China, says GlobalData.

95
article thumbnail

MRC Laboratory of Medical Sciences worth £120m opens on ICL campus

Pharma Times

The institute is one of two UK laboratories wholly funded by the MRC

124
124